# Presentation: 247786

## Director’s Report to the

**Director’s Report to the**
**National Advisory Council**
**on Drug Abuse**

**     ****February 7, 2007**

## Laura S. Rosenthal

***NIDA Executive Officer and ***
***Associate Director for Management***
**Retired on January 3, 2007 **
**after 39 Years of **
**Government Service—**
**the last 17 with NIDA**

## Donna M. JonesActing  Director, OPRM and

**Acting Executive Officer, NIDA**

## Slide 4

## NIDA  BUDGET

**NIDA  BUDGET**

**(Thousands)**

**Increase **
**Over **
**Prior Year**

**AIDS**

**TOTAL**

**NonAIDS**

**  ****$693,282**

**  ****$313,137**

**2005****Actual**

**$1,006,419**

**+1.2%**

**$698,976**

**$299,882**

**2006****Actual**

**  ****$998,858**

**-0.8%**

**2007****C.R.**

**$699,349**
**$300,073**
**$999,422**
**     **

**   ****+0.1%**

**2008****P.B.**

**   ****$699,908**
**   ****$300,457**
**$1,000,365**
**    ****+0.1%**

***Scheduled Budget Hearings:***
***March 1 -- House Labor/HHS Subcommittee -- ******SAMHSA, NIDA, NIMH & NIAAA***
***March 6 – House Labor/HHS Subcommittee --  NIH***

## National Institutes of Health Reform Act of 2006

**National Institutes of Health Reform Act of 2006**

**On January 15, the President signed the NIH Reform Act, following unanimous support by the Congress.  **
**The legislation authorizes a new process to facilitate trans-NIH research.**

## Key Provisions in the Bill

**Key Provisions in the Bill**

**Establishes ****Division of Program Coordination, Planning, & Strategic Initiatives (DPCPSI)**** within Office of the Director**
**Common Fund **
**Council of Councils to advise on research proposals**
**Establishes ****Scientific Management Review Board (SMRB)**** to conduct organizational reviews and make recommendations**
**Authorizes**** (but does not appropriate) ****an increase in NIH funding**** for each of the next 3 years**
**Requires ****public process for reorganizing**** NIH programs**
**Many reporting requirements are eliminated or subsumed **
**    ****in new biennial report**

## NIH Director Has Selected Dr. Alan M. Krensky as

**NIH Director Has Selected ****Dr. Alan M. Krensky**** as**
**NIH Deputy Director for the Office of **
**Portfolio Analysis & Strategic Initiatives (OPASI) **

**Professor of Pediatrics**
**Chief of the Division of Immunology &**
**   ****Transplantation Biology**
**Associate Chair for Research in the **
**   ****Department of Pediatrics and**
**Associate Dean for Children’s Health **
**   ****at Stanford University School of Medicine **

## NIH Fiscal Policy for Grant Awards – FY 2007

**NOT-OD-030 – Released December 15, 2006**

***Inflationary adjustments for existing non-competing renewal awards will not be made in FY 2007***
**Each IC will manage it’s portfolio by using savings from not funding inflationary increases to maintain the stability of the NIH investigator pool ( 9600 new and competing RPGs)**
**Guidelines to give special consideration in order of priority:**
**1)  ****New investigators**** (# comparable to past 5 years)**
**First time grantees applying for their ****first renewal**** **
**Grantees with ****insufficient other support**

## IC Directors’ Retreat – January 4, 2007

**IC Directors’ Retreat – January 4, 2007**
**Roadmap II**

**Top 5 Topics**

**Strategic Planning Groups**

**1) Microbiome**
**2) Protein Capture/Proteome Tools**
**3) Phenotyping Services, Tools**
**4) Inflammation**
**5) Epigenetics **
**     *****(Concept Development Groups for***
***      ******these Top 5 topics will be created) ***

**a) Training/Careers**
**b) Health Disparities **
**c) Science of Science **
**d) Pharmacogenomics**

## Facilitating Interdisciplinary Research via

**Facilitating Interdisciplinary Research via**
** ****Methodological and Technological Innovation **
**in the Behavioral and Social Sciences (R21) **
**Roadmap Initiative – NIDA is Lead**
**(RFA-RM-07-004)**
** **

## NIDA Council Workgroups

**NIDA Council Workgroups**

## Addressing Recommendations of the

**Addressing Recommendations of the**
** ****Basic Science Review Workgroup**

**Brain Blueprint: Neurodevelopment**
**Intent of RFA: “Study of Drug Abuse, Risky Decision Making & HIV/AIDS” **

***Invest in...social neuroscience & epigenetics, ...pain and HIV***

***Further enhance current efforts in the area of development: ***

**PA DA-07-166 Functional Genetics and Genomics of Drug Addiction**
**RFA DA-07-003 Mechanisms of Drug Abuse Interactions with HIV Neuropathogenesis**
**RFA DA-06-005 “Pain and Opiate Addiction” ****10 grants funded**
**RFA DA- 06-004 “Social Neuroscience”  ****7 grants funded**

**PA DA-07-166 Functional Genetics and Genomics of Drug Addiction**
**RFA DA-06-007 Epigenetics of Addiction ****12 grants funded**
**With NIEHS, potential Epigenetics Roadmap II activity**

## Addressing Recommendations of the

**Addressing Recommendations of the**
** ****Basic Science Review Workgroup**

***Increase support for and nurture young investigators***
***  ***
**B/START PAR reissued.  Targets new investigators in behavioral science**
**EChem released.  Targets new investigators in medicinal chemistry**
**Travel awards for young investigators:  APA, CPDD, SfN**
***Strengthen dissemination of information about DBNBR services***
**Drug supply – Program:  disseminating drug supply and analytical services information to research investigators on CDs and e-mail.**
**Genetics Repository and related DBNBR services to grantees – **
**e-mail distribution list; Planned RFI; Genetics Webpage **

## Addressing Recommendations of the

***within DBNBR and across Divisions within NIDA***
**DBNBR has worked across Divisions within NIDA to develop **
**initiatives on:**
**   ****Social Neuroscience (with NIDA and other ICs) **
**   ****HIV Neuropathogenesis**
**   ****Addiction to Prescription Medications**
**   ****GEDI **
**   **
**   ****Adolescence and Development (with NIDA and other ICs) **

**Addressing Recommendations of the**
** ****Basic Science Review Workgroup**

## NIDA

**NIDA**

**National Institute ****on**** Drug Abuse**

**Special Populations Office**

**Division of **
**Basic Neurosciences**
**& Behavior Research**

**Office of**
**Extramural **
**Affairs**

**Office of Planning**
**& Resource**
** ****Management**

**Office of **
**Science Policy & **
**Communications**

** ****Intramural **
**Research**
**Program**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Division of**
**Pharmacotherapies &**
**Medical Consequences**
**of Drug Abuse**

**Center for the**
**Clinical Trials **
**Network**

**Teresa Levitin, PhD**

**Laura Rosenthal**

**Timothy Condon, PhD**

**Betty Tai, PhD**

**David Shurtleff, PhD**

**Frank Vocci, PhD**

**Wilson Compton, MD, MPE**

**Barry Hoffer, MD, PhD**

**Office of the Director**

**Nora D. Volkow, MD**

** ****Director**

**Timothy P. Condon, Ph.D.**

**Deputy Director**

**Laura S. Rosenthal**

**Associate Director**
**for Management**

** ****Division of Clinical**
**Neuroscience &**
**Behavioral Research**

**Joseph Frascella, PhD**

**Director, AIDS Research**

**DBNBR**

## Genes with Overlapping Function

**Neurexin1**

**PKCE**

**nAChRs**

**VPS13A**

**Chloride channels**

**L1CAM**

**RELN**

**GRM**

**AGER**

**GPSM3**

**NOTCH4**

**TRP7**

**RNF5**

**ST18**

**AGPAT1**

**Perlegen/WashU**
_**Nicotine Dependence**_

**GATA binding protein**

**PKCE**

**SYT14L**

**OR5AK**

**GATA binding protein**

**SLC35B4**

**PPP1R3A**

**Utrophin**

**OFCC1**

**LSM11**

**HB1**

**PHF15**

**PPP3CA**

**NrCAM**

**PDE11A**

**TSSC1**

**RGS5**

**Neurexin3**

**RYR3**

**Intramural**
_**Drug Abuse**_

**SYT14L**

**Notes:**
Shown here are the top genes from the Pelegen  study and top genes from the IRP study looking at drug addiction across more heterogeneous population and across several drugs of abuse.  While the genes in these tow lists are not identical they can be classified into genes related to synaptic plasticity including those involved in cell adhesion, neurotransmission, signal transduction and gene transcription

## MANY OF THESE GENES HAVE SYNAPTIC FUNCTIONS

**Dean and Dresbach, TINS, 2006**

**      ****CELL **
**ADHESION**

**      ****NEURO-**
**TRANSMISSION**

**         ****SIGNAL **
**TRANSDUCTION**

**TRANSCRIPTION ****       FACTORS**

**MANY OF THESE GENES HAVE SYNAPTIC FUNCTIONS**

**Notes:**
Functionally many of these genes are involved in  synaptic formation and cell signaling as shown here for example neurexin found with both Perlegen and IRP a presynaptic cell adhesion protein that binds with a postsynaptic protein neroligin which is involved in synaptic formation . While the other genes discovered are involved in modulating neurotransmission, signal transduction and gene transcription. 

## Extinction and Pharmacotherapies 

**Extinction and Pharmacotherapies **
**for Drug Addiction**
** ****(R01--RFA-DA-07-010)**
** ****(R03--RFA-DA-07-011)**

## NIDA

**NIDA**

**National Institute ****on**** Drug Abuse**

**Special Populations Office**

**Division of **
**Basic Neurosciences**
**& Behavior Research**

**Office of**
**Extramural **
**Affairs**

**Office of Planning**
**& Resource**
** ****Management**

**Office of **
**Science Policy & **
**Communications**

** ****Intramural **
**Research**
**Program**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Division of**
**Pharmacotherapies &**
**Medical Consequences**
**of Drug Abuse**

**Center for the**
**Clinical Trials **
**Network**

**Teresa Levitin, PhD**

**Laura Rosenthal**

**Timothy Condon, PhD**

**Betty Tai, PhD**

**David Shurtleff, PhD**

**Frank Vocci, PhD**

**Wilson Compton, MD, MPE**

**Barry Hoffer, MD, PhD**

**Office of the Director**

**Nora D. Volkow, MD**

** ****Director**

**Timothy P. Condon, Ph.D.**

**Deputy Director**

**Laura S. Rosenthal**

**Associate Director**
**for Management**

** ****Division of Clinical**
**Neuroscience &**
**Behavioral Research**

**Joseph Frascella, PhD**

**Director, AIDS Research**

**DCNBR**

## Damage to the Insula 

**Damage to the Insula **
**Disrupts Addiction to**
**Cigarette Smoking**

***Source: Naqvi, NH et al., Science 315: 531-534, January 26, 2007.***

## Brain Imaging Drug Use Prevention

**Brain Imaging Drug Use Prevention**
** ****Messags (R21)**
**(RFA-DA-07-007)**
**DCNBR and DESPR**

## NIDA

**NIDA**

**National Institute ****on**** Drug Abuse**

**Special Populations Office**

**Division of **
**Basic Neurosciences**
**& Behavior Research**

**Office of**
**Extramural **
**Affairs**

**Office of Planning**
**& Resource**
** ****Management**

**Office of **
**Science Policy & **
**Communications**

** ****Intramural **
**Research**
**Program**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Division of**
**Pharmacotherapies &**
**Medical Consequences**
**of Drug Abuse**

**Center for the**
**Clinical Trials **
**Network**

**Teresa Levitin, PhD**

**Laura Rosenthal**

**Timothy Condon, PhD**

**Betty Tai, PhD**

**David Shurtleff, PhD**

**Frank Vocci, PhD**

**Wilson Compton, MD, MPE**

**Barry Hoffer, MD, PhD**

**Office of the Director**

**Nora D. Volkow, MD**

** ****Director**

**Timothy P. Condon, Ph.D.**

**Deputy Director**

**Laura S. Rosenthal**

**Associate Director**
**for Management**

** ****Division of Clinical**
**Neuroscience &**
**Behavioral Research**

**Joseph Frascella, PhD**

**Director, AIDS Research**

**DPMCDA**

## Combination of Lofexidine and THC 

**Combination of Lofexidine and THC **
**Was Most Effective at Decreasing **
**MJ Withdrawal Symptoms, MJ Craving & Relapse**

## Development of Immunotherapeutic Products

**Development of Immunotherapeutic Products**
** ****for the Treatment of **
**Methamphetamine Addiction (U01)**
**(RFA-DA-07-004)**

## NIDA

**NIDA**

**National Institute ****on**** Drug Abuse**

**Special Populations Office**

**Division of **
**Basic Neurosciences**
**& Behavior Research**

**Office of**
**Extramural **
**Affairs**

**Office of Planning**
**& Resource**
** ****Management**

**Office of **
**Science Policy & **
**Communications**

** ****Intramural **
**Research**
**Program**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Division of**
**Pharmacotherapies &**
**Medical Consequences**
**of Drug Abuse**

**Center for the**
**Clinical Trials **
**Network**

**Teresa Levitin, PhD**

**Laura Rosenthal**

**Timothy Condon, PhD**

**Betty Tai, PhD**

**David Shurtleff, PhD**

**Frank Vocci, PhD**

**Wilson Compton, MD, MPE**

**Barry Hoffer, MD, PhD**

**Office of the Director**

**Nora D. Volkow, MD**

** ****Director**

**Timothy P. Condon, Ph.D.**

**Deputy Director**

**Laura S. Rosenthal**

**Associate Director**
**for Management**

** ****Division of Clinical**
**Neuroscience &**
**Behavioral Research**

**Joseph Frascella, PhD**

**Director, AIDS Research**

**DESPR**

## Source: Monitoring the Future Study, 2006

***Source: Monitoring the Future Study, 2006***

## Issues of Concern: 

**9.6**

**10.5**

**9.3**

**0.0**

**2.0**

**4.0**

**6.0**

**8.0**

**10.0**

**12.0**

**      ****OxyContin**

**      ****Vicodin**

**2002**

**2003**

**2004**

**4.0**

**4.5**

**5.0**

**Percent of 12****th**** Graders**

***Issues of Concern: ***
**Past Year Nonmedical Use of **
**OxyContin and Vicodin Remains High**

**5.5**

**9.5**

**2005**

**4.3**

**9.7**

**2006**

*****

***  Significant decline between 2005 and 2006**

***     ******Nearly 1 in 10 Seniors Have Abused Vicodin***

***Source: Monitoring the Future Study, 2006***

## Prevalence of Past Year Drug Use Among 12th graders

**2006 Monitoring the Future Study**

*** Nonmedical use**

***Source: Monitoring the Future Study, 2006***

## Reported Daily Smoking is at Historically Low Levels

*****

*****

*****

*** ****Significant decline between 2001 and 2006**

***Source: Monitoring the Future Study, 2006***

**Notes:**
New

## NIDA

**NIDA**

**National Institute ****on**** Drug Abuse**

**Special Populations Office**

**Division of **
**Basic Neurosciences**
**& Behavior Research**

**Office of**
**Extramural **
**Affairs**

**Office of Planning**
**& Resource**
** ****Management**

**Office of **
**Science Policy & **
**Communications**

** ****Intramural **
**Research**
**Program**

**Division of**
**Epidemiology, **
**Services & **
**Prevention Research **

**Division of**
**Pharmacotherapies &**
**Medical Consequences**
**of Drug Abuse**

**Center for the**
**Clinical Trials **
**Network**

**Teresa Levitin, PhD**

**Laura Rosenthal**

**Timothy Condon, PhD**

**Betty Tai, PhD**

**David Shurtleff, PhD**

**Frank Vocci, PhD**

**Wilson Compton, MD, MPE**

**Barry Hoffer, MD, PhD**

**Office of the Director**

**Nora D. Volkow, MD**

** ****Director**

**Timothy P. Condon, Ph.D.**

**Deputy Director**

**Laura S. Rosenthal**

**Associate Director**
**for Management**

** ****Division of Clinical**
**Neuroscience &**
**Behavioral Research**

**Joseph Frascella, PhD**

**Director, AIDS Research**

**CCTN**

## CTN STAGE-12 Protocol

**Evaluate reduction in percent days of stimulant use**
**Secondary objectives: **
**     ****evaluate reduction in use of other drugs, **
**     ****involvement in 12-step activities and meetings, **
**     ****and how involvement mediates drug use outcomes**
**Study population of approximately 400 stimulant users**
**DSMB approved the protocol on January 29, 2007**
**Enrollment expected to begin September 2007**

**CTN STAGE-12 Protocol**

## “NIDA Goes to the Doctor” 

**“*****NIDA Goes to the Doctor*****” **
**Initiative**

**HBO Special -- March 15, 2007**

**Centers of Excellence**

## Centers of Excellence 

***“******Health Professionals Substance Abuse  Education Act”*****  **
**– ****a multi-pronged bill intended to better train**
**doctors to recognize substance abuse and properly refer patients**
**and their families for treatment NIDA will establish**

**Centers of Excellence**** **

**RFP Issued in the Fall of 2006 through the **
**American Medical Association-Medical **
**Education Research Consortium **

***Awards Issued to:***
**Creighton University School of Medicine**
**University of Pennsylvania School of Medicine/**
**        ****Drexel University College of Medicine**
**University of North Dakota School of Medicine & Health Sciences**
**Massachusetts Consortium of Medical Schools**

## Recent and Upcoming Meetings,

**Recent and Upcoming Meetings,**
**Conferences and Events**

## Slide 36

## Slide 37

## Slide 38